Pharmaron Beijing Co., Ltd.

SZSE:300759 Stock Report

Market Cap: CN¥44.6b

Pharmaron Beijing Future Growth

Future criteria checks 2/6

Pharmaron Beijing is forecast to grow earnings and revenue by 6% and 13.6% per annum respectively. EPS is expected to grow by 5.7% per annum. Return on equity is forecast to be 12.6% in 3 years.

Key information

6.0%

Earnings growth rate

5.7%

EPS growth rate

Life Sciences earnings growth29.1%
Revenue growth rate13.6%
Future return on equity12.6%
Analyst coverage

Good

Last updated14 Oct 2024

Recent future growth updates

Recent updates

Pharmaron Beijing Co., Ltd. (SZSE:300759) Shares Fly 29% But Investors Aren't Buying For Growth

Sep 27
Pharmaron Beijing Co., Ltd. (SZSE:300759) Shares Fly 29% But Investors Aren't Buying For Growth

Pharmaron Beijing Co., Ltd. (SZSE:300759) Shares Could Be 22% Below Their Intrinsic Value Estimate

Sep 20
Pharmaron Beijing Co., Ltd. (SZSE:300759) Shares Could Be 22% Below Their Intrinsic Value Estimate

Pharmaron Beijing Co., Ltd.'s (SZSE:300759) Intrinsic Value Is Potentially 69% Above Its Share Price

May 12
Pharmaron Beijing Co., Ltd.'s (SZSE:300759) Intrinsic Value Is Potentially 69% Above Its Share Price

Pharmaron Beijing Co., Ltd.'s (SZSE:300759) 27% Share Price Surge Not Quite Adding Up

Mar 04
Pharmaron Beijing Co., Ltd.'s (SZSE:300759) 27% Share Price Surge Not Quite Adding Up

Pharmaron Beijing (SZSE:300759) Seems To Use Debt Quite Sensibly

Feb 27
Pharmaron Beijing (SZSE:300759) Seems To Use Debt Quite Sensibly

Earnings and Revenue Growth Forecasts

SZSE:300759 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202616,2222,2151,9993,17615
12/31/202514,2951,9691,6932,86417
12/31/202412,5971,837N/A2,56116
6/30/202411,5021,9282582,573N/A
3/31/202411,4851,4833902,969N/A
12/31/202311,5381,601-1122,754N/A
9/30/202311,4241,553-2142,777N/A
6/30/202311,2721,575-5722,564N/A
3/31/202310,8871,474-8062,255N/A
1/1/202310,2661,375-8072,143N/A
9/30/20229,5451,582-7072,037N/A
6/30/20228,7931,682-3002,072N/A
3/31/20228,0571,664-2421,977N/A
12/31/20217,4441,661-352,058N/A
9/30/20216,8491,423-1521,905N/A
6/30/20216,2261,258-791,876N/A
3/31/20215,6641,3171251,822N/A
12/31/20205,1341,1723331,649N/A
9/30/20204,7171,0085321,565N/A
6/30/20204,3148654401,283N/A
3/31/20203,9535943701,124N/A
12/31/20193,757547184939N/A
9/30/20193,499437146837N/A
6/30/20193,274378247906N/A
3/31/20193,089346230861N/A
12/31/20182,908333150791N/A
9/30/20182,713300-721692N/A
12/31/20172,294231N/A552N/A
12/31/20161,634177N/A236N/A
12/31/20151,12874N/A217N/A
12/31/201479021N/A12N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300759's forecast earnings growth (6% per year) is above the savings rate (2.9%).

Earnings vs Market: 300759's earnings (6% per year) are forecast to grow slower than the CN market (23.7% per year).

High Growth Earnings: 300759's earnings are forecast to grow, but not significantly.

Revenue vs Market: 300759's revenue (13.6% per year) is forecast to grow faster than the CN market (13.5% per year).

High Growth Revenue: 300759's revenue (13.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 300759's Return on Equity is forecast to be low in 3 years time (12.6%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y